Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells

Patients with advanced chronic myeloid leukemia (CML) have a poor prognosis, with the use of tyrosine kinase inhibitors (TKIs) to treat CML demonstrating poor results. The results of the present study revealed that, following Cell Counting Kit-8 analysis, treatment of K562 cells with decitabine (DAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Li-Cai, Luo, Jian-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529866/
https://www.ncbi.nlm.nih.gov/pubmed/28789344
http://dx.doi.org/10.3892/ol.2017.6318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529866/
https://www.ncbi.nlm.nih.gov/pubmed/28789344
http://dx.doi.org/10.3892/ol.2017.6318

Ejemplares similares